Compare SRTS & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRTS | YI |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 57.1M |
| IPO Year | 2016 | 2018 |
| Metric | SRTS | YI |
|---|---|---|
| Price | $3.87 | $6.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 33.0K | 9.4K |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.03 | $2.48 |
| 52 Week High | $5.92 | $11.17 |
| Indicator | SRTS | YI |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 46.00 |
| Support Level | $3.66 | $6.20 |
| Resistance Level | $3.92 | $7.18 |
| Average True Range (ATR) | 0.22 | 0.37 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 3.03 | 20.22 |
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.